The EUROPEAN RESPIRATORY JOURNAL, published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, is at the forefront of advancing knowledge in the fields of pulmonary and respiratory medicine. With its ISSN 0903-1936 and E-ISSN 1399-3003, this esteemed journal has established itself as a leading platform since its inception in 1988, currently converging towards 2024. Ranked in the Q1 category for both Medicine (miscellaneous) and Pulmonary and Respiratory Medicine in 2023, it stands as the 3rd of 155 journals in its field, reflecting an impressive 98th percentile Scopus ranking. The journal boasts a rigorous selection of peer-reviewed articles that encompass innovative research, clinical studies, and reviews, thereby enhancing the understanding and treatment of respiratory diseases. Although it does not currently offer an Open Access option, the journal remains crucial for researchers, clinicians, and healthcare professionals committed to improving respiratory health across Europe and beyond. Join a community dedicated to groundbreaking research and advancements in respiratory medicine.

The Lancet Respiratory Medicine, published by Elsevier in the United Kingdom, is a premier journal dedicated to the field of pulmonary and respiratory medicine. With its impressive impact factor and a prestigious ranking of #1 out of 155 in its category as of 2023, it holds a remarkable position in advancing research and clinical practices in respiratory health. The journal invites original research, reviews, and clinical studies that aim to propel the understanding of respiratory diseases, fostering innovations in treatment and management strategies. Operating under a Q1 category in Scopus rankings, it is an essential platform for researchers, healthcare professionals, and students who are committed to enhancing patient care and advancing knowledge in this crucial area of medicine. The Lancet Respiratory Medicine remains a vital resource for the latest findings and discussions shaping the future of respiratory health.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

Welcome to the Journal of Thoracic Disease, a premier scholarly journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by AME PUBLISHING COMPANY in Hong Kong, this journal has established itself as a critical platform for the dissemination of innovative research and clinical advancements since its inception in 2009. With an impressive Q2 ranking in the Scopus category of Pulmonary and Respiratory Medicine, it is recognized for its contribution to the academic community, featuring a broad range of original research, reviews, and case studies that address contemporary challenges in thoracic disease management. The journal is committed to Open Access principles, ensuring that high-quality research is readily available to a global audience, further enhancing its impact factor and reach. Researchers, healthcare professionals, and students alike will find invaluable insights within its pages, making Journal of Thoracic Disease an essential resource for those invested in the respiratory health domain.

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

JTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.

ONCOLOGIST is a premier, open-access journal published by Oxford University Press, advancing the field of cancer research since its inception in 1996. With an impressive H-Index and a prestigious placement within the Q1 category in Cancer Research, Medicine, and Oncology for 2023, ONCOLOGIST stands at the forefront of oncological science, boasting a Scopus rank of #55 out of 404 in Medicine and #47 out of 230 in Cancer Research. This journal not only disseminates cutting-edge research but also aims to foster multidisciplinary approaches that are critical for addressing the complex challenges faced in cancer therapy and survivorship. Be part of a vibrant community as you explore impactful research articles that contribute to the global conversation on cancer. ONCOLOGIST is dedicated to providing an accessible platform for authors and readers alike, ensuring that high-quality research is available to all stakeholders in the fight against cancer.

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

Lung Cancer Management, published by FUTURE MEDICINE LTD, is a premier academic journal dedicated to the evolving field of oncology and respiratory medicine. With an ISSN of 1758-1966 and an E-ISSN of 1758-1974, this journal offers a platform for the dissemination of cutting-edge research, clinical studies, and expert reviews, all focusing on the latest advances in lung cancer treatment and management. Despite being a relatively new entry since its inception in 2014 and achieving its converged years from 2020 to 2024, it has already established itself in the Q3 quartile for both oncology and pulmonary and respiratory medicine as of 2023, according to category quartiles rankings. With a Scopus ranking of #98 in the category of Pulmonary and Respiratory Medicine and #266 in Oncology, the journal reflects a commitment to quality and relevance in its content. Although it does not offer open access, it remains a crucial resource for researchers, clinicians, and students seeking to stay informed about the latest developments and practical approaches in lung cancer management. The journal is accessible from its base in the United Kingdom, at UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ensuring that it caters to a global audience eager to explore and contribute to this vital field of medicine.

Cancer Medicine is a leading open access journal published by WILEY, focusing on innovative research and advancements in the fields of Cancer Research, Oncology, and Radiology, with an impressive impact evidenced by its 2023 Q2 ranking in Cancer Research and Q1 rankings in both Oncology and Radiology, Nuclear Medicine and Imaging. With an ISSN of 2045-7634, this journal has been committed to disseminating pivotal findings since its inception in 2012, serving as a vital platform for researchers, practitioners, and students alike. The journal proudly embodies the spirit of open access, ensuring that groundbreaking cancer research is accessible to a global audience. Located in the United Kingdom, it spans a wide array of topics, promising comprehensive insights into cancer therapies, molecular mechanisms, and imaging techniques, thereby significantly contributing to the enhancement of cancer care and treatment outcomes. Researchers interested in exploring the latest advancements in cancer medicine will find this journal an indispensable resource.